Objective: To describe the burden of COVID-19 in a children’s multidisciplinary hospital for two years of the pandemic, taking into account of age, severity of the disease, the spectrum of underlying conditions and the intensive care need.Methods: An assessment of 6048 cases of COVID-19 in patients under 18 years of age hospitalized from March 26, 2020 to December 31, 2021 was carried out. The diagnosis was confirmed by PCR on an outpatient basis or after hospitalization with the help of diagnostic kits registered in the Russian Federation. The features of the work of a children’s multidisciplinary hospital in new conditions, the dynamics of hospitalization, age characteristics and new coronavirus (CV) infection severity in the pandemic development process are presented. The analysis of the underlying condition’s structure depending on the severity of the disease, as well as the need and volume of therapy in the intensive care unit. The frequency and main characteristics of children’s multisystem inflammatory syndrome (MIS-C) in hospital conditions, long-term PCR positivity and its effect on the duration of inpatient treatment of children have been established.Results: The spread of SARS-COV-2 in St. Petersburg required a radical change in the work of the children’s multidisciplinary hospital. During the two years of the pandemic, four waves of hospitalization of children with new CV were revealed, differing in duration, intensity, and frequency of lung damage, but having no significant differences in the proportion of severe forms of the disease (1.7-2.8% of cases). Intensive therapy was required in 3.6% of cases, of which only 1/3 was due to the severe course of COVID-19 with a lung lesion volume of up to 100%. In 1/3 of cases, patients had risks of developing severe forms and in 1/3 – other pathology. Severe course of new CV was significantly more often accompanied by the need for respiratory support, anticoagulants and anti-inflammatory therapy. Contributing factors of severe forms and unfavorable outcomes were: pathology of the central nervous system, genetic diseases and malformations, obesity, as well as chronic bronchopulmonary pathology. Mortality in the hospital was recorded only among children with severe underlying conditions (0.1% of cases). D-MVS was registered significantly more often in boys (7 out of every 10 patients), accounting for 1.2% of cases of hospitalization of children with new CV over the entire period. Convalescent PCR-positivity in the outcome of COVID-19 was detected in 1/3 of children, significantly more often during the autumnwinter waves of the pandemic and among patients of high school age.Conclusion: New CV is gradually strengthening its position in the structure of acute respiratory pathology in children. Some of SARS-COV-2 infection cases is accompanied by extensive lung damage, as well as severe systemic inflammation independently or in the other infectious diseases structure, induction of the debut of various somatic pathology is not excluded. The presented data confirm the need for increased attention at high risk of adverse respiratory diseases outcomes children. All severe cases of COVID-19 in children require a personalized approach, taking into account the existing background diseases and possible options for the progression of the process. MIS-C should be considered as a systemic inflammatory response syndrome within the framework of an infectious disease of various etiologies, differentiated with Kawasaki disease and the debut of systemic diseases. The long-term PCR-positivity in the outcome of COVID-19 requires further study to address the need and nature of therapy in order to prevent further spread of infection in the population.

Since March 2020, the first reports have appeared about the increasing, almost everywhere, number of children who have undergone a new coronovirus infection caused by SARS-Cov-2 with a symptom complex resembling the manifestations of Kawasaki disease. A special feature of the clinical manifestations of this syndrome, which is called “Pediatric multisystem inflammatory syndrome associated with COVID-19”, is the high incidence of life-threatening conditions caused by the sharp development of arterial hypotension against the background of cardiogenic or vasogenic shock.In St. Petersburg, since the end of November 2020, there has been a sharp surge in admissions of children to the ICU of various hospitals with the clinic of Pediatric multisystem inflammatory syndrome, who have laboratory confirmation of the transferred COVID-19.The purpose of this article is to attract the attention of doctors of various profiles, to combine efforts to study this pathology, to determine the criteria for verifying the diagnosis, optimal treatment regimens and dispensary monitoring of patients who have been ill.

This paper reviews the development stages of theoretical knowledge about the interferon, its properties and important role in the human immune system as well as interferon-based medications for preventive and therapeutic use There have been created various interferon-based medications with different administration routes for the treatment of acute respiratory viral infections (ARVI), viral eye diseases, herpetic infections of the skin and mucous membranes, allergic and gynecological diseases This article also discusses the domestic experience with the use of original interferon-based medication Grippferon® for the prevention and treatment of ARVI, including influenza, parainfluenza, respiratory syncytial virus, adenovirus and coronavirus infections, as well as measles and rubella in patients of all age groups (especially in elderly people, pregnant women and nursing mothers, children from the first days of life, newborns and premature babies with low and very low birth weight) An increase in the efficacy of the interferon-based medications has been proven, given that they are used when the first disease symptoms appear (English) [ABSTRACT FROM AUTHOR] В настоящем обзоре изложены этапы развития теоретических знаний о свойствах интерферона (ИФН) и его значимости в иммунном статусе человеческого организма, а также о создании на основе данного белка медицинского препарата (рекомбинантного ИФН-α-2b) для профилактического и терапевтического применения Была создана серия препаратов с разными методами введения для лечения острой респираторной вирусной инфекции, вирусных заболеваний глаз, герпетических поражений кожи и слизистых оболочек, аллергических и гинекологических заболеваний В работе представлен отечественный опыт применения ИФН α-2b (Гриппферон®) для профилактики и лечения респираторных вирусных инфекций, в т ч гриппа, парагриппа, респираторно-синцитиальных, адено-, коронавирусных инфекций, а также кори и краснухи у пациентов любого возраста (пожилых лиц, беременных женщин и кормящих матерей, а также детей первого года жизни и новорожденных, в т ч недоношенных с низкой и очень низкой массой тела при рождении) Доказано увеличение эффективности препаратов при условии их применения с момента появления первых симптомов заболевания (Russian) [ABSTRACT FROM AUTHOR] Copyright of Farmateka is the property of LLC Bionika Media and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )

Thearticle presents the results of years of studies (including biochemical and immunological) of the effectiveness of application and prophylaxis (in relation to nosocomial infections) and the safety of antiviral chemical preparation Arbidol in 694 children with influenza and influenza-like illness, including the coronavirus infection (43 children) and combined lesions of respiratory tract (150), indicating the possible inclusion of the drug in the complex therapy for children with the listed diseases, regardless of the severity and nature of their course. The studies were conducted according to the regulated standard of test conditions and randomized clinical trials.

Comparative analysis of the clinical laboratory data from 419 children and 468 adults hospitalized during the pandemic of A (H1N1pdm 2009) and pre- and post-pandemic periods (2010-2013) showed that the clinical presentation of the pandemic influenza in patients of all ages is generally typical for influenza, and its character is determined by the degree of involvement of lungs in the process. Besides, the incidence of pneumonia in adults is statistically significantly higher than in children. During all compared periods hyperthermia (≥39°C), hemorrhagic and dyspeptic syndrome were observed. Some differences in the main clinical manifestations of pneumonia in recovered patients and patients who died of the severe pandemic influenza were observed. The regularities of the cytokine reactions depending on the intensity of intoxication and occurrence of complications were determined in patients of all ages. Medical efficacy of inclusion of antiviral chemotherapeutic agents into complex influenza treatment was proved.

Flu monitoring was carried out in children’s general hospital in St. Petersburg within three epidemic seasons (2010–2011, 2011–2012 and 2012–2013). 1916 patients under the age of 18 years were examined with the complex of virologic tests . The natural decreasing of flu incidence and predominant diagnosing in etiologic structure one of the virus serotypes [in the first A(H1N1)pdm09, in the second — A(H3N2)] have been observed during the first two years after a pandemic. In the third season restoration of the main characteristics of epidemic flu situation were detected: polietiology with annual change of serotypes proportions, late start (winter and spring), majority of younger children among hospitalaized patients and a mild course of disease. The most probable candidates [viruses of a subtype A(H3N2)] are revealed as a causal factor of significant increasing of disease incidence with the severe forms in the near future. Laboratory data were confirmed by increase in frequency of the complicated by pneumonia ARI at hospitalized patients during the periods of their maximum registration. All isolates received during the study were corresponded to the referens-strains included in vaccines. Thus, timely and appropriate vaccination during the studied period had to become an effective protection against a flu.

We evaluated the percent of acute respiratory viral infections with gastrointestinal syndrome in the structure of morbidity in babies aging 6 months and elder. Therapeutic efficiency and safety of anaferon (pediatric formuation) as a component of complex therapy of acute respiratory viral infections with involvement of the gastrointestinal tract were proven; more rapid disappearance of all symptoms and improvement of the immune status parameters were demonstrated.